Brooklyn Immunotherapeutics Inc (BTX)

0.55
0.00(0.87%)
Pre Market
0.56
+0.01(+0.94%)
- Real-time Data
  • Volume:
    280,188
  • Day's Range:
    0.55 - 0.59
  • 52 wk Range:
    0.45 - 13.63
Earnings results expected today

BTX Overview

Prev. Close
0.55
Day's Range
0.55-0.59
Revenue
-
Open
0.59
52 wk Range
0.45-13.63
EPS
-1.98
Volume
280,188
Market Cap
32.64M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
586,084
P/E Ratio
-
Beta
2.44
1-Year Change
-94.77%
Shares Outstanding
58,825,739
Next Earnings Date
Aug 18, 2022
What is your sentiment on Brooklyn Immunotherapeutics?
or
Market is currently closed. Voting is open during market hours.

Brooklyn Immunotherapeutics Inc Analysis

Brooklyn Immunotherapeutics Inc Company Profile

Brooklyn Immunotherapeutics Inc Company Profile

Employees
10

Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellNeutralSellStrong Sell
Technical IndicatorsStrong SellSellStrong SellBuyStrong Sell
SummaryStrong SellStrong SellSellNeutralStrong Sell
  • https://seekingalpha.com/news/3716338-brooklyn-immunotherapeutics-completes-acquisition-of-novellus-therapeutics
    0
    • Back to 16
      0
      • Why???
        0
        • hold to watch
          0
          • ?? any news?Wall Street analysts have assigned a consensus price target?
            0
            • Buy 🌚
              0
              • loaded at dip will back to 20 soon
                0
                • up back to 20 very soon and long term up all the way
                  0
                  • what down today?
                    0
                    • 30 soon
                      0